Noxilizer appoints Christopher A. Thatcher as new CEO

Mission to scale organization to meet the accelerating demand for NO2 sterilization

Noxilizer’s Board of Directors announces the appointment of Christopher A. Thatcher as President & CEO effective May 13. He has also joined the Board of Directors. Chris brings a proven track record of experience in early-stage private and publicly held medical device companies, US and global markets, and commercial success in business-to-business and business-to-consumer environments. He has held senior management positions in Integra Life Sciences and Bausch and Lomb. At Neuronetics, Chris served as President and CEO, raised significant capital, and took the company public in an IPO. He serves on the Board of Directors for Micro Interventional Devices and as a strategic advisor for Sinaptica Therapeutics.

“Noxilizer is on a rapid growth trajectory and Chris’s experience in successfully leading companies at this stage is critical,” states Lawrence Bruder, Executive Chairman of the Noxilizer Board of Directors and most recently served as President & CEO. Bruder continues, “This is an especially important time, as two global biotech companies are awaiting final regulatory approval of their products using NO2 sterilization.”

Pharmacetical, biotech and medical device companies are driving the demand for Noxilizer’s proprietary and ultra-low temperature NO2 sterilization process. With the increasing regulatory and environmental guideline changes for ethylene oxide, NO2 is the leading alternative sterilization method for their current and future products.

“This is an exciting and much needed sterilization technology for the life sciences market and offers a safe and effective process for workers and patients,” states Christopher Thatcher. “I am looking forward to building on the company’s success and brining my experience in commercial operations, operationalizing strategies, aligning the organization and growing the team to support our customer’s needs.”

NO2 sterilization offers several key advantages: ultra-low temperature (10°-30°C), minimal pressure requirements, no/minimal residuals, and fast cycle times (6 – 12 hours, including aeration). NO2 sterilization opens new avenues for innovation and has been shown to be particularly effective in the sterilization of pre-filled syringes, drug-device combination products, and custom implants. 

For more information about NO2 sterilization, contact Maura Kahn at

About Noxilizer, Inc.:

Noxilizer is a fast-growing medical technology company that provides ultra-low temperature nitrogen dioxide sterilization that offers many benefits over traditional sterilization methods. Our customers are the leading global pharmaceutical, biotech and medical device companies developing the next generation of products. Noxilizer products and services include feasibility studies, validation, contract sterilization, consulting, sterilization equipment, consumable product line, and customer and technical service. Noxilizer’s headquarters are in Hanover, MD. For more information, please visit:

Noxilizer Press Contact:
Maura O. Kahn
Senior Vice President, Commercial
O (443) 842-4403
C (202) 744-6337

Scroll to Top